Exxel Pharma

Exxel Pharma is a privately held company founded in 2017 with a focus on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The company's lead program, EX937, is a first-in-class, proprietary small molecule designed for refractory chronic cough, an underserved market affecting approximately 10% of the global population. EX937 leverages a differentiated approach by inhibiting the FAAH enzyme, demonstrating efficacy and favorable safety in modulating chronic cough in preclinical models. The company is rapidly advancing the development of EX937 towards a first-in-human Phase 1/1b study. Additionally, EX937 holds the potential to be utilized across blockbuster indications including hyperactive bladder, peripheral neuropathic pain, and migraine headaches. Despite the absence of specific information regarding headquarter location and recent investment details, Exxel Pharma's dedication to addressing unmet medical needs and its unique therapeutic approach presents promising opportunities in the Health Care and Pharmaceutical industries for potential investors.